Fontenot A P, Kotzin B L, Comment C E, Newman L S
Department of Medicine, National Jewish Medical and Research Center Center, Denver, Colorado 80206, USA.
Am J Respir Cell Mol Biol. 1998 Apr;18(4):581-9. doi: 10.1165/ajrcmb.18.4.2981.
Chronic beryllium disease (CBD) is a granulomatous disorder characterized by the presence of noncaseating granulomas and mononuclear cell inflammation, occurring in 1 to 5% of people exposed to beryllium in the workplace. In the lungs of affected patients, CD4(+) T cells accumulate. Using anti-T-cell receptor (TCR) monoclonal antibodies, we investigated the TCR beta and alpha variable (Vbeta and Valpha, respectively) repertoire in the bronchoalveolar lavage (BAL) and blood of both CBD patients and healthy controls. There was marked heterogeneity within the BAL CD4(+) T-cell repertoire in both patients and controls. However, 11 of the 28 CBD patients demonstrated 16 different T-cell subset expansions within the BAL as compared with only one expansion in ten healthy controls. Five of the 16 expansions in CBD patients expressed Vbeta3. Altered TCR expression within the BAL T-cell repertoire appeared to persist over time in patients who underwent repeat evaluation. After in vitro stimulation of BAL T cells with beryllium sulfate and interleukin-2, we noted further alteration of the BAL TCR repertoire in some individuals. These results provide additional insight into the involvement of CD4(+) T cells in this disease and form the basis for studies to examine the nature of the stimulating antigen.
慢性铍病(CBD)是一种肉芽肿性疾病,其特征为出现非干酪样肉芽肿和单核细胞炎症,在 workplace 接触铍的人群中,发病率为 1%至 5%。在受影响患者的肺部,CD4(+) T 细胞会积聚。我们使用抗 T 细胞受体(TCR)单克隆抗体,研究了 CBD 患者和健康对照者支气管肺泡灌洗(BAL)液及血液中的 TCR β 和 α 可变区(分别为 Vβ 和 Vα)库。患者和对照者的 BAL CD4(+) T 细胞库均存在明显的异质性。然而,28 例 CBD 患者中有 11 例在 BAL 中出现了 16 种不同的 T 细胞亚群扩增,而 10 名健康对照者中仅有 1 例出现扩增。CBD 患者的 16 种扩增中有 5 种表达 Vβ3。接受重复评估的患者,其 BAL T 细胞库中 TCR 表达的改变似乎会持续存在。在用硫酸铍和白细胞介素-2 对 BAL T 细胞进行体外刺激后,我们注意到部分个体的 BAL TCR 库进一步发生了改变。这些结果为深入了解 CD4(+) T 细胞在该疾病中的作用提供了更多线索,并为研究刺激抗原的性质奠定了基础。